52 Firmen mit Ergebnissen für "怎么查酒店开房信息- 查询微信10 1"

ETH Entrepreneurship

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18


 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

ETH Entrepreneurship

Wagistrasse 18

8952 Schlieren

9172 Ergebnisse für "怎么查酒店开房信息- 查询微信10 1" unter ETH Entrepreneurship

1

... to aquatic organisms. 48 hr EC/LC50 Fathead minnow: 1- 10 mg/L, toxic 72 hr EC/LC50 Algae: 0.72 mg/L ... 48 hr EC/LC50 Fathead minnow: 1- 10 mg/L, toxic 72 hr EC/LC50 Algae: 0.72 mg/L, very toxic DATA FOR ... to aquatic organisms. 48 hr EC/LC50 Fathead minnow: 1- 10 mg/L, toxic 72 hr EC/LC50 Algae: 0.72 mg/L ... 48 hr EC/LC50 Fathead minnow: 1- 10 mg/L, toxic 72 hr EC/LC50 Algae: 0.72 mg/L, very toxic DATA FOR ... 1 ...

Slide 1

... Highly-Compact 1-Ф PFC Rectifier ■ Two Interleaved 1.65 kW Systems PO = 3.3kW UN = 230V± 10% UO = 400V fP ... Slide 1 Johann W. Kolar Swiss Federal Institute of Technology (ETH) Zurich Power Electronic Systems ... Highly-Compact 1-Ф PFC Rectifier ■ Two Interleaved 1.65 kW Systems PO = 3.3kW UN = 230V± 10% UO = 400V fP ... Slide 1 ... Slide 1 ...

Mehr Ergebnisse

University of Zurich

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

University of Zurich

Wagistrasse 12

8952 Schlieren

12767 Ergebnisse für "怎么查酒店开房信息- 查询微信10 1" unter University of Zurich

Microsoft Word - 05_2007101800709203_FullPaper_查.doc

... NPV-PVa % 0.7 0.2 1.0 0.1 Crown LAI - 2.5 1 10 0.5 b CC % 0.6 0.2 0.80 0.1 LAD Spherical Stand ... , Michael.Schaepman, Jan.Clevers)@wur.nl Commission VII, WG VII/ 1 KEY WORDS: Chlorophyll Content, Non-Photosynthetic ... NPV-PVa % 0.7 0.2 1.0 0.1 Crown LAI - 2.5 1 10 0.5 b CC % 0.6 0.2 0.80 0.1 LAD Spherical Stand ... , Michael.Schaepman, Jan.Clevers)@wur.nl Commission VII, WG VII/ 1 KEY WORDS: Chlorophyll Content, Non-Photosynthetic ... Microsoft Word - 05_2007101800709203_FullPaper_ .doc ...

Slide 1

... Slide 1 6th Winter Brain Symposium, Sils Maria Time Sunday, February 28 Monday, March 1 Tuesday ... Chair: J. Growdon Chair: R. Glockshuber Chair: C. Hock 08:30-08:50 T. Welt J. Bali V. Finder 08:50-09: 10 ... Slide 1 ... Slide 1 6th Winter Brain Symposium, Sils Maria Time Sunday, February 28 Monday, March 1 Tuesday ... Slide 1 ...

Mehr Ergebnisse

Somagenetix

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

Somagenetix

Wagistrasse 23

8952 Schlieren

23677 Ergebnisse für "怎么查酒店开房信息- 查询微信10 1" unter Somagenetix

Folie 1

... tro l (n =6 ) m as (n = 1 4) f a s ( n= 11 ) 0 5 10 15 20 *p<0.05; 2way ANOVA followed by Bonf ... -7M ERα-Agonist 10-7M ERβ-Agonist vehicle (mean= 1) 10-8M E2 Mean±SEM, n=4 carried out in triplicates ... tro l (n =6 ) m as (n = 1 4) f a s ( n= 11 ) 0 5 10 15 20 *p<0.05; 2way ANOVA followed by Bonf ... -7M ERα-Agonist 10-7M ERβ-Agonist vehicle (mean= 1) 10-8M E2 Mean±SEM, n=4 carried out in triplicates ... Folie 1 ...

1-s2.0-S0167701219307444-main.pdf

... after 48 hours of incubation at 37°C ± 1°C. For treatment with CAAP, three concentrations ( 10- 1, 10-2 ... ) on different concentrations (left row 10^- 1, middle row 10^-2 and right row 10^-3 bacteria) of ... after 48 hours of incubation at 37°C ± 1°C. For treatment with CAAP, three concentrations ( 10- 1, 10-2 ... ) on different concentrations (left row 10^- 1, middle row 10^-2 and right row 10^-3 bacteria) of ... 1-s2.0-S0167701219307444-main.pdf ...

Mehr Ergebnisse

University Hospital Zurich​, Research and Education Office

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

University Hospital Zurich​, Research and Education Office

Rämistrasse 100

8091 Zürich

1224 Ergebnisse für "怎么查酒店开房信息- 查询微信10 1" unter University Hospital Zurich​, Research and Education Office

Folie 1

... Program Tuesday, January 10, 2017 Auditorium NORD 1 – Frauenklinik, University Hospital Zürich (USZ ... Folie 1 ANNUAL MEETING 2017 Challenges in perinatal and neonatal infectious diseases How to find ... Program Tuesday, January 10, 2017 Auditorium NORD 1 – Frauenklinik, University Hospital Zürich (USZ ... Folie 1 ... Folie 1 ...

Folie 1

... Folie 1 Stem Cell Transplantation for AL Amyloidosis Ute Hegenbart, MD Amyloidosis Center ... University Heidelberg Medical Dept. V / Hematology / Stem cell transplant Unit Zürich, 19.06.2014, 1 ... Folie 1 ... Folie 1 Stem Cell Transplantation for AL Amyloidosis Ute Hegenbart, MD Amyloidosis Center ... Folie 1 ...

Mehr Ergebnisse

Blutspende SRK Zürich

https://www.blutspendezuerich.ch/  

8952 Schlieren, Rütistrasse 19

 +41 58 272 52 52
 info@zhbsd.ch

The Zurich Blood Transfusion Service SRK (ZHBSD) is a nonprofit foundation and independent partner in the healthcare sector. It ensures the supply of blood and blood products to patients in the Zurich region. Our products are made exclusively from voluntary, unpaid blood donations. We offer our services at cost-covering prices and without government subsidies. Along with ten other regional blood donation services in Switzerland, we are a member of the Swiss Red Cross Blood Donation Service (BSD SRK AG).

Blutspende SRK Zürich

Rütistrasse 19

8952 Schlieren

309 Ergebnisse für "怎么查酒店开房信息- 查询微信10 1" unter Blutspende SRK Zürich

Folie 1

... . 1: Schematic RHD/RHCE gene locus showing the 10 exons and common RH1 negative or very weak variants ... Folie 1 RHD DONOR SCREENING IN SWITZERLAND: RESOLVING NOVEL ALLELES BY NANOPORE-SEQUENCING S ... . 1: Schematic RHD/RHCE gene locus showing the 10 exons and common RH1 negative or very weak variants ... Folie 1 ... Folie 1 ...

Folie 1

... Folie 1 ADVERSE REACTIONS IN APHERESIS DONORS: A 10 YEAR RETROSPECTIVE ANALYSIS AT ZHBSD Maria ... and Table 1. The result of our retrospective 10-year analysis shows that apheresis procedures at ZHBSD ... Folie 1 ADVERSE REACTIONS IN APHERESIS DONORS: A 10 YEAR RETROSPECTIVE ANALYSIS AT ZHBSD Maria ... and Table 1. The result of our retrospective 10-year analysis shows that apheresis procedures at ZHBSD ... Folie 1 ...

Mehr Ergebnisse

InSphero AG

http://www.insphero.com  

8952 Schlieren, Wagistrasse 27

 +41 44 515049-0
 info@insphero.com

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company currently counts all of the top ten global pharmaceutical and cosmetics companies as customers and is helping them to implement its patented microtissue technology in their development work-flow.

InSphero AG

Wagistrasse 27

8952 Schlieren

318 Ergebnisse für "怎么查酒店开房信息- 查询微信10 1" unter InSphero AG

Slide 1

... Slide 1 1 1 0 1 0 0 1 0 0 0 0 5 0 1 0 0 1 5 0 2 0 0 S ita x s e n ta n (µ M ) C e ll v ia b il it y ... 0 = M4 32 .8 IC 5 0 = M1 90 .9 IC 5 0 = M3 48 . 1 H u m a n H e p /H u m a n N P C 1 1 0 1 0 0 1 0 ... Slide 1 1 1 0 1 0 0 1 0 0 0 0 5 0 1 0 0 1 5 0 2 0 0 S ita x s e n ta n (µ M ) C e ll v ia b il it y ... 0 = M4 32 .8 IC 5 0 = M1 90 .9 IC 5 0 = M3 48 . 1 H u m a n H e p /H u m a n N P C 1 1 0 1 0 0 1 0 ... Slide 1 ...

Folie 1

... Folie 1 Institutsname / Partner Logo Institute of Radiation Biology Identification of compounds ... 1. 3D-microtissue analysis platforms - changes in 3D-microtissue growth followed by high content ... Folie 1 Institutsname / Partner Logo Institute of Radiation Biology Identification of compounds ... 1. 3D-microtissue analysis platforms - changes in 3D-microtissue growth followed by high content ... Folie 1 ...

Mehr Ergebnisse

Roche Glycart AG

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

Roche Glycart AG

Wagistrasse 10

8952 Schlieren

3023 Ergebnisse für "怎么查酒店开房信息- 查询微信10 1" unter Roche Glycart AG

OP-EHEA190412 1..61

... OP-EHEA190412 1..61 2019 ESC Guidelines for the diagnosis and management of acute pulmonary ... Mainz, Building 403, Langenbeckstr. 1, 55131 Mainz, Germany. Tel: þ49 613 117 6255, Fax: þ49 613 117 ... OP-EHEA190412 1..61 ... OP-EHEA190412 1..61 2019 ESC Guidelines for the diagnosis and management of acute pulmonary ... OP-EHEA190412 1..61 ...

cobas® HIV-1 Test

... - 1 for use on the cobas® 4800/5800/6800/8800 Systems, a next-generation, dual-target quantitative HIV ... - 1 assay, only from Roche. The cobas® HIV- 1 quantitative nucleic acid test for use on the cobas® 4800 ... cobas® HIV- 1 Test ... https://diagnostics.roche.com/be/en/products/params/cobas-hiv- 1-test.html ... cobas® HIV- 1 Test ...

Mehr Ergebnisse

Bio-Technopark Schlieren-Zürich

http://www.bio-technopark.ch/  

8952 Schlieren, Wagistrasse 23

 +41 76 336 99 44
 mario.jenni@bio-technopark.ch

The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.

Bio-Technopark Schlieren-Zürich

Wagistrasse 23

8952 Schlieren

151 Ergebnisse für "怎么查酒店开房信息- 查询微信10 1" unter Bio-Technopark Schlieren-Zürich

1. Digital Health Lab Day › BIO-TECHNOPARK® Schlieren-Zürich

... 1. Digital Health Lab Day Event date: 03.10.2019 1. Digital Health Lab Day – Life in numbers 5 on ... 1. Digital Health Lab Day › BIO-TECHNOPARK® Schlieren-Zürich ... https://www.bio-technopark.ch/en/events-en/external-events/ 1-digital-health-lab-day/ ... 1. Digital Health Lab Day › BIO-TECHNOPARK® Schlieren-Zürich ...

Molecular Partners Announces First Patient Dosed in Phase 1 Trial o...

... News Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor ... announced that the first patient has been enrolled and dosed in a Phase 1 first-in-human study of MP0310 as ... Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor ... - 1-trial-of-mp0310-a-novel-tumor-localized-immunotherapy/ ... Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor ...

Mehr Ergebnisse

Neurimmune Therapeutics AG

http://www.neurimmune.com  

8952 Schlieren, Wagistrasse 18

 +41 44 755 46 46
 info@neurimmune.com

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.

Neurimmune Therapeutics AG

Wagistrasse 18

8952 Schlieren

74 Ergebnisse für "怎么查酒店开房信息- 查询微信10 1" unter Neurimmune Therapeutics AG

Neurimmune - 19.02.2017: BIIB076 Moves into Phase 1 for Alzheimer's...

... February 19, 2017 BIIB076 Moves into Phase 1 for Alzheimer's Disease BIIB076 has moved into phase 1 ... NovaGo Therapeutics raises CHF 10 million to develop regenerative anti-Nogo therapy for stroke March 1 ... Neurimmune - 19.02.2017: BIIB076 Moves into Phase 1 for Alzheimer's Disease ... Neurimmune - 19.02.2017: BIIB076 Moves into Phase 1 for Alzheimer's Disease ...

Neurimmune - 07.03.2013: Biogen presents the first clinical data fr...

... Neurimmune March 7, 2013 Biogen presents the first clinical data from an ongoing Phase 1 study of ... clinical data from an ongoing Phase 1 trial, as well as new data on a direct comparison of mouse versions ... Neurimmune - 07.03.2013: Biogen presents the first clinical data from an ongoing Phase 1 study of ... -ongoing-phase- 1-study-of-biib037-in-mild-to-moderate-alzheimers.html ... Neurimmune - 07.03.2013: Biogen presents the first clinical data from an ongoing Phase 1 study of ...

Mehr Ergebnisse

Repertoire Immune Medicines (Switzerland) AG

https://www.repertoire.com/  

8952 Schlieren, Wagistrasse 27


 info@repertoire.com

The key to our strategy lies in understanding the inner workings of the immune synapse – the interaction between the T cell and the antigen presenting cell which dictates the immune code that tells a T cell to become toxic and to kill the infected tissue. Our scientists created and developed the DECODETM and DEPLOY suite of technologies, which allows in-depth characterization of TCR-antigen pairings – and the ability to rationally design and clinically develop targeted immune medicines. Our scientists also have developed novel technologies that attach potent immunomodulators to T cells, enabling us to deliver potent cytokines such as IL-15 or IL-12 directly to tumors by using the natural homing power of the T cells to traffic to diseased tissue.

Repertoire Immune Medicines (Switzerland) AG

Wagistrasse 27

8952 Schlieren

25 Ergebnisse für "怎么查酒店开房信息- 查询微信10 1" unter Repertoire Immune Medicines (Switzerland) AG

Repertoire Immune Medicines Launches Type 1 Diabetes Focused Progra...

... 1 Diabetes CAMBRIDGE AND BOSTON, MA – March 25, 2020 – Repertoire Immune Medicines, a newly launched ... -changing solutions to cure, prevent and treat type 1 diabetes (T1D). The investment from the JDRF T1D Fund ... Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D ... https://www.repertoire.com/about/press-releases/repertoire-immune-medicines-launches-type- 1 ... Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D ...

Repertoire Immune Medicines to Present Data from Autologous T Cell ...

... obtained from applying its proprietary antigen-specific TCR-MHC DECODE™ platform in its Phase 1 trial ... be presented at the American Association of Cancer Research (AACR) Virtual Meeting Week 1 , taking ... ) Virtual Meeting Week 1 , taking place April 10-15, 2021. PRIME IL-15, the company’s lead investigational ... ™ platform in its Phase 1 trial evaluating PRIME IL-15 (RPTR-147) in patients with advanced or metastatic ...

Mehr Ergebnisse

Mehr Firmen

Nach oben